Skip to content
The Nexus
DossierENTITY

Mark Goldsmith

Coverage of Mark Goldsmith in the Nexus archive.

Earliest in view: May 30 · 13:25 UTCMost recent: May 30 · 13:25 UTC
Co-mentioned in this coverage
Revolution Medicinesorganization1daraxonrasibtopic1Food and Drug Administrationorganization1pancreatic cancertopic1Phase 3 clinical trialtopic1STATorganization1
Recent coverage
  • HEALTHMay 30 · 13:25 UTCSTAT NEWS
    STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug

    Revolution Medicines has started shipping its experimental pancreatic cancer drug daraxonrasib to patients under an FDA-authorized early access program. The drug, not yet approved, showed in a Phase 3 trial that patients lived nearly twice as long as those receiving standard chemotherapy.

Mark Goldsmith · Dossier · The Nexus